Brought to you by 
Genentech pays $35mm up front for Actelion's Tracleer
10 Apr 2020
Executive Summary
Genentech agreed to pay (uf)$35mm up front for the right to co-promote Actelion's pulmonary hypertension and chronic heart failure drug Tracleer (bosentan), in the US, upon the drug's approval for both indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech pays $35mm up front for Actelion's Tracleer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice